Biotech Values

[zipjet]

MNTA - after listening to the CC

The mild market reaction seems appropriate.

My guess is EPS out one or two quarters will be cut 10-20 cents ps each Q as the expenses of development ramp up. Of course, the bet is that those costs will be returned and much more on success at launching a biosimilar or better an interchangeable biologic.

Thus, for the next couple of years, earnings will depend on mL and if approved mC.

The Baxter deal does assure a path for the company.

It is clear that they do not expect other FoB deals for at least several years.

ij